» Articles » PMID: 22772323

Increased Production of IL-5 and Dominant Th2-type Response in Airways of Churg-Strauss Syndrome Patients

Overview
Specialty Rheumatology
Date 2012 Jul 10
PMID 22772323
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Churg-Strauss syndrome (CSS) is a rare systemic vasculitis associated with eosinophilia and asthma. We assessed the local immune response in airways of CSS patients with different activity of the disease.

Methods: Concentration of IL-5, CCL17, CCL22 and CCL26 (ELISA) together with cell expression of T-helper-related genes (real-time PCR array) were measured in bronchoalveolar lavage fluid (BALF) sampled from 11 patients with active CSS, 11 patients with CSS in remission and 9 control subjects with bronchial asthma.

Results: In active CSS, both BALF and blood eosinophil counts were increased (P<0.01). BALF cells in active disease were characterized by an increased expression of Th2 and regulatory-type transcripts: STAT6, STAT3, GATA3, IL4, IL5 and IL10 as compared with asthmatics, and STAT5A, CCR4, FOXP3, IL4, IL5 and IL10 when compared with inactive CSS. There was significant increase in BALF concentration of IL-5 and CCL26 in exacerbation of CSS. CCR4-active chemokines were detected more frequently in active disease. We found a strong positive correlation between clinical parameters of disease activity (BVAS, eosinophilia) and expression of IL4, IL5, IL10 and STAT5A.

Conclusion: These results indicate that as compared with asthma, active-CSS patients have much stronger local Th2 response in the airways. Airway cells may contribute to lung eosinophilia in CSS by producing IL-5 and eosinophil active chemokines.

Citing Articles

Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.

Hua L, Xie M Ther Adv Respir Dis. 2025; 19:17534666251318615.

PMID: 39980304 PMC: 11843704. DOI: 10.1177/17534666251318615.


Three cases of relapsed eosinophilic sinusitis without eosinophilia during mepolizumab maintenance therapy for eosinophilic granulomatosis with polyangiitis.

Nishisaka K, Ueda Y, Inoue M, Ishikawa M, Kageyama G, Saegusa J Clin Rheumatol. 2024; 43(11):3577-3580.

PMID: 39249645 DOI: 10.1007/s10067-024-07133-w.


The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.

Szymczyk A, Jaworski J, Podhorecka M Cent Eur J Immunol. 2024; 49(1):60-69.

PMID: 38812609 PMC: 11130981. DOI: 10.5114/ceji.2024.136512.


Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity and Anti-SCR HIV-1 Effects.

Sadeghi L, Bolhassani A, Mohit E, Baesi K, Aghasadeghi M Curr HIV Res. 2024; 22(2):109-119.

PMID: 38712371 DOI: 10.2174/011570162X297602240430142231.


Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.

Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A Front Immunol. 2023; 14:1204444.

PMID: 37457743 PMC: 10349177. DOI: 10.3389/fimmu.2023.1204444.